A patient with chronic widespread pain, fatigue, sleep disturbance, and cognitive symptoms can reasonably meet criteria for fibromyalgia. The same patient, if they have a history of long-term benzodiazepine use with a recent taper, can also fit the description of benzodiazepine-induced neurological dysfunction (BIND). Depending on which clinician does the evaluation, either label may be applied, and the label shapes the treatment course substantially. For patients who have received a fibromyalgia diagnosis and also have a relevant benzodiazepine history, the question is worth revisiting: which framework actually fits, and what does that imply for management.
What Fibromyalgia Is Under Current Criteria
Fibromyalgia, as defined by the American College of Rheumatology’s 2010 and 2016 updated criteria, is a syndrome of chronic widespread pain accompanied by fatigue, unrefreshing sleep, cognitive symptoms, and somatic symptom burden. The diagnosis uses the Widespread Pain Index and the Symptom Severity Scale; tender point examination, once central to the diagnosis, has been de-emphasized in the current criteria.
Fibromyalgia is understood mechanistically as a nociplastic pain syndrome: pain arising from altered nociceptive processing rather than from identifiable tissue injury or inflammation. Central sensitization — amplified central nervous system response to sensory input — is the dominant conceptual framework. Autonomic features, mood symptoms, and small-fiber neuropathy findings are present in subsets of patients but are not required for diagnosis.
What BIND Is
BIND, as described by Ritvo and colleagues in 2023, refers to the persistent neurological, cognitive, and autonomic symptoms that can follow prolonged benzodiazepine exposure, including in patients who tapered carefully. The syndrome includes sensory hypersensitivity, musculoskeletal pain, cognitive dysfunction, autonomic instability, sleep disruption, mood changes, and a course that often extends many months after the drug is discontinued. Central sensitization is part of the proposed mechanism, alongside durable GABA-A receptor adaptation and secondary neuroinflammation.
BIND and fibromyalgia therefore share a mechanistic substrate — central sensitization — and share multiple clinical features. The distinguishing variable is the causal history.
Where the Labels Diverge in Practice
Three features typically differentiate a BIND-driven presentation from a primary fibromyalgia presentation in a patient where both are being considered.
The temporal relationship to benzodiazepine exposure. Symptoms that appeared during or after a benzodiazepine taper, or that emerged after years of use in a pattern consistent with tolerance or protracted withdrawal, support a BIND framework. Symptoms that predate any benzodiazepine exposure, or that emerged years before any change in prescribing, support a primary fibromyalgia framework. Patients who had both — pre-existing fibromyalgia exacerbated by benzodiazepine exposure and taper — are common, and this combination warrants being stated explicitly rather than collapsed into a single diagnosis.
The autonomic and sensory picture. BIND typically involves more prominent autonomic instability (temperature dysregulation, orthostasis, cardiovascular lability) and sensory hypersensitivity (to light, sound, touch, medications, and foods) than primary fibromyalgia. Fibromyalgia can include these features but they are usually less dominant.
The variability. BIND shows a windows-and-waves course with clear flares after dose changes or stressors and partial resolution between. Fibromyalgia fluctuates but generally without the same time-locking to specific pharmacologic events.
Why the Label Matters for Treatment
Standard fibromyalgia treatments include exercise (graded, typically aerobic), cognitive-behavioral therapy, and pharmacologic options: duloxetine, milnacipran, pregabalin, gabapentin, and low-dose tricyclic antidepressants (amitriptyline). Each has meaningful evidence in fibromyalgia and is a reasonable first-line intervention for patients with primary fibromyalgia.
Applied to a patient with BIND, several of these options carry specific concerns.
Pregabalin and gabapentin. These drugs act on the alpha-2-delta subunit of voltage-gated calcium channels. They produce physical dependence with their own withdrawal syndromes that resemble benzodiazepine withdrawal in many respects. Adding them to a patient with BIND often provides initial symptom reduction but commits the patient to an eventual second taper. For patients still on a benzodiazepine, it adds another drug to the long-term deprescribing picture.
Duloxetine and milnacipran (SNRIs). These produce discontinuation syndromes of their own and can be challenging to taper. They are not benzodiazepine-like in mechanism, and their addition is less disruptive than gabapentinoids, but the deprescribing-interests consideration still applies.
Tricyclic antidepressants at low doses. Amitriptyline at 10 to 25 mg at bedtime is sometimes tolerated and can help with sleep and pain. The anticholinergic burden is the main concern in a BIND population that is often already sensitized to anticholinergic effects.
Exercise. Graded exercise is evidence-based in fibromyalgia. It is often poorly tolerated in BIND, where post-exertional amplification of symptoms — closer to the pattern seen in ME/CFS than in fibromyalgia — is common. Pacing is usually more appropriate than graded exposure.
CBT. Useful in both populations, with the caveat that CBT framed as treatment for a psychological condition (rather than as a tool for living with a neurological syndrome) can reinforce the sense of dismissal that many BIND patients have already encountered.
The Practical Resolution
In a patient with fibromyalgia features and a relevant benzodiazepine history, several steps produce a more useful diagnostic and treatment plan than either label alone.
Establish whether BIND is a plausible contributor by review of the medication timeline, the relationship of symptom onset to benzodiazepine dose changes, and the autonomic and sensory features that are more specific to BIND. If the answer is yes, the diagnosis is at least “fibromyalgia with BIND contribution” — and often primarily BIND with features that happen to meet fibromyalgia criteria.
Prioritize the taper and autonomic stabilization. If the patient is still on a benzodiazepine, the taper is the primary intervention. If the taper is complete, time and general support for autonomic recovery take precedence over aggressive pharmacologic treatment of the pain picture.
Avoid committing to fibromyalgia-specific pharmacotherapy as the central management strategy if BIND is a significant contributor. The risk of adding medications with their own dependence and discontinuation profiles to a patient still navigating the original benzodiazepine is rarely worth the limited analgesic benefit at this stage.
Consider specific interventions that address both frameworks: sleep support with minimal pharmacologic risk (sleep hygiene, CBT-I where available), pacing rather than graded exercise, low-dose naltrexone in selected patients (discussed separately), and symptomatic management of specific features as they emerge.
Revisit the diagnosis over time. BIND-dominant pictures typically improve over months to years with abstinence and autonomic stabilization. Fibromyalgia that persists after the BIND trajectory has resolved is clearer evidence of a primary fibromyalgia component and can be treated accordingly.
A Note on Patients Who Carry Both Labels
For patients who already have a fibromyalgia diagnosis and later identify BIND, the prior label does not need to be removed. Both can be recorded, with the understanding that each framework captures part of the clinical picture. The treatment choices should then reflect the priority of the BIND contribution while the taper and recovery are active, with fibromyalgia-specific treatment reserved for residual symptoms that persist after BIND-dominant recovery.
The diagnostic collision between fibromyalgia and BIND is one of the more common pitfalls in this clinical territory. Recognizing it allows the treatment plan to match the underlying mechanism rather than defaulting to whichever label was applied first.